Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INSR | P06213 | 15/20 | 0.60 |
| ▸ | IGF1R | P08069 | 15/20 | 0.60 |
| ▸ | ALK | Q9UM73 | 15/20 | 0.60 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | ULK1 | O75385 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | ROS1 | P08922 | 1/20 | 0.43 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15217781 | 0.89 | ALK (0.62) | INSRIGF1RALKEGFRULK1 | |
| SCHEMBL15217784 | 0.86 | ALK (0.82) | INSRIGF1RALKMAP4K1EGFR | |
| SCHEMBL19203857 | 0.84 | ALK (0.56) | INSRIGF1RALKAURKA | |
| SCHEMBL3890386 | 0.82 | ALK (0.77) | INSRIGF1RALK | |
| SCHEMBL22515632 | 0.76 | ALK (0.81) | INSRIGF1RALKMAP4K1EGFR | |
| SCHEMBL11916548 | 0.75 | ALK (1.00) | INSRIGF1RALKMAP4K1EGFR | |
| SCHEMBL11916314 | 0.75 | ALK (0.78) | INSRIGF1RALKMAP4K1EGFR | |
| SCHEMBL19203872 | 0.74 | LRRK2 (0.69) | INSRIGF1RALKEGFRAURKA | |
| SCHEMBL11916421 | 0.73 | ALK (0.84) | INSRIGF1RALKMAP4K1EGFR | |
| SCHEMBL11916497 | 0.73 | ALK (0.90) | INSRIGF1RALKEGFRAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012462-B2 | Phosphorous derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | PHKA1, PIK3CA, PHKA2 | INSR 751/4885IGF1R 477/4885ALK 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.